Key Highlights
- IAM shares rose 18.73% in today's session to $14.07 from a prior close of $11.85.
- Third-quarter collaboration Revenue was $11.4 million, up from $4.7 million a year earlier.
- Pro forma cash and cash equivalents were about $455 million after the October IPO.
- IAM1363 showed a 36% systemic and 41% intracranial best overall response rate.
Iambic (NASDAQ:IAM) shares climbed in today's session, a day after the AI-driven drug discovery company reported third-quarter results and a Business update. The stock was at $14.07, up 18.73% from the prior close of $11.85, and remains below the $16.00 IPO price. Volume was about 322,000 shares.
Iambic is a San Diego-based, clinical-stage life sciences and technology company that pairs its Enchant and NeuralPLexer AI models with automated chemistry and biology experiments to design small-molecule oncology medicines. Its shares began trading on Nasdaq on October 15, and the 52-week range runs from $9.60 to $25.00.
What Did Iambic Report for the Third Quarter?
Collaboration revenue was $11.4 million, up from $4.7 million a year earlier on discovery collaborations. Research and Development expenses rose to $34.1 million from $23.1 million, and general and administrative expenses rose to $7.4 million from $4.3 million. Net loss widened to $38.5 million from $21.5 million and included a $10.4 million non-cash charge from the change in Fair Value of convertible notes that converted into common stock before the IPO closed.
Cash and cash equivalents were $252 million at September 30. Pro forma cash was about $455 million, including about $156 million of net IPO proceeds and $47 million of upfront payments from AbbVie (NYSE:ABBV) received in October. The IPO of 10,781,250 shares at $16.00 raised gross proceeds of $172.5 million. Year to date, collaboration revenue was about $24 million, billings from collaborations were about $100 million and total operating expenses were about $108 million.
How Did the IAM1363 Data Look?
Updated data from the ongoing Phase 1/2 study of IAM1363, a brain-penetrant HER2 inhibitor, were presented at ESMO 2026 with an August 31 data cutoff. In heavily pretreated patients dosed at 960 mg or more once daily, best overall response was a partial response in 36% (19 of 53) by RECIST v1.1 and 41% (9 of 22) for intracranial activity by RANO-BM.
Fifteen participants had remained on study for at least six months. Among 68 patients at 960 mg, 5.9% had a grade 3 treatment-related adverse event, and none had a grade 4 or 5 event. Iambic plans to start a registrational study in HER2-positive breast cancer in 2027, subject to FDA regulatory approval.
Which Partnerships and Pipeline Programs Matter Next?
Iambic entered a multi-year collaboration with AbbVie in September covering immunology, neuroscience and oncology, and a collaboration with Bayer in June. A program milestone in the Takeda (NYSE:TAK) collaboration, which was announced in February, triggered a $1.0 million payment. The company has signed eight partnerships since 2024.
For IAM217, a KIF18A inhibitor, Iambic submitted an IND on September 30 and received a Safe-to-Proceed Letter from the FDA for a Phase 1/2 trial. The IND for IAM-C1, a CDK2/4 inhibitor, is on track for the fourth quarter, with Phase 1/2 initiation expected in early 2027.
Data Presentations and the IND Filing Set the Next Checkpoints
Iambic will present preclinical data for IAM217 and IAM-C1 at the EORTC-NCI-AACR Symposium in Barcelona, with IAM217 data scheduled for November 18 to 20. The IAM-C1 IND submission and the planned IAM1363 registrational study are the next milestones.


_11_17_2026_19_45_07_327614.jpg)
_11_17_2026_18_59_44_560836.jpg)


Please wait processing your request...